Loading
A phase 3 trial of Zongertinib, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Boehringer Ingelheim, active and no longer recruiting.
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment is a phase 3 interventional study registered as NCT06151574 by Boehringer Ingelheim, with 428 participants enrolled, started 2024-02-09 and due to reach its primary completion in 2026-09-02. Interventions recorded: zongertinib, pembrolizumab, cisplatin, carboplatin and pemetrexed.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zongertinib, Boehringer Ingelheim, Pemetrexed, Cisplatin and the tag pipeline.
Shares Zongertinib, Boehringer Ingelheim, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/